“BRAF-mutant Non-Small Cell Lung Cancer (NSCLC) Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the BRAF-mutant Non-Small Cell Lung Cancer Market.
The BRAF-mutant Non-Small Cell Lung Cancer Pipeline report embraces in-depth commercial, regulatory, and BRAF-mutant Non-Small Cell Lung Cancer clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging BRAF-mutant Non-Small Cell Lung Cancer drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
BRAF-mutant Non-Small Cell Lung Cancer (NSCLC) Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the emerging therapies for BRAF-mutant Non-Small Cell Lung Cancer treatment and the aggregate therapies developed by major pharma companies.
-
It accesses the different BRAF-mutant Non-Small Cell Lung Cancer therapies segmented into early-stage, mid-stage, and late-stage of clinical development.
-
It outlines the major BRAF-mutant Non-Small Cell Lung Cancer companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
The report evaluates the BRAF-mutant Non-Small Cell Lung Cancer drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the BRAF-mutant Non-Small Cell Lung Cancer therapeutics market.
BRAF-mutant Non-Small Cell Lung Cancer (NSCLC) Therapeutics Landscape
There are approx. 10+ key companies developing therapies for BRAF-mutant Non-Small Cell Lung Cancer. Currently, Pierre Fabre Medicament is leading the therapeutics market with its BRAF-mutant Non-Small Cell Lung Cancer drug candidates in the most advanced stage of clinical development.
BRAF-mutant Non-Small Cell Lung Cancer (NSCLC) Companies Actively Working in the Therapeutic Market Include:
-
Pierre Fabre Medicament
-
Xynomic Pharmaceuticals, Inc.
-
Kinnate Biopharma
-
Revolution Medicines, Inc.
-
Black Diamond Therapeutics, Inc.
And Many Others
Emerging and Marketed BRAF-mutant Non-Small Cell Lung Cancer (NSCLC) Drugs Covered in the Report Include:
-
Encorafenib/Binimetinib: Pierre Fabre Medicament
-
XP-102: Xynomic Pharmaceuticals, Inc.
And Many More
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and BRAF-mutant Non-Small Cell Lung Cancer Companies Working in the Market @
Analysis of Emerging BRAF-mutant Non-Small Cell Lung Cancer Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Route of Administration
BRAF-mutant Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Intra-articular
-
Intraocular
-
Intrathecal
-
Intravenous
-
Ophthalmic
-
Oral
-
Parenteral
-
Subcutaneous
-
Topical
-
Transdermal
Molecule Type
Products have been categorized under various Molecule types such as
-
Oligonucleotide
-
Peptide
-
Small molecule
Learn How the BRAF-mutant Non-Small Cell Lung Cancer Treatment Outlook will Evolve with the Ongoing Clinical and commercial Activities in the Therapeutic Market @
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. BRAF-mutant Non-Small Cell Lung Cancer Treatment Patterns
4. BRAF-mutant Non-Small Cell Lung Cancer – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. BRAF-mutant Non-Small Cell Lung Cancer Late Stage Products (Phase-III)
7. BRAF-mutant Non-Small Cell Lung Cancer Mid-Stage Products (Phase-II)
8. BRAF-mutant Non-Small Cell Lung Cancer Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. BRAF-mutant Non-Small Cell Lung Cancer Discontinued Products
13. BRAF-mutant Non-Small Cell Lung Cancer Product Profiles
14. Major BRAF-mutant Non-Small Cell Lung Cancer Companies in the Market
15. Key Products in the BRAF-mutant Non-Small Cell Lung Cancer Therapeutics Segment
16. Dormant and Discontinued Products
17. BRAF-mutant Non-Small Cell Lung Cancer Unmet Needs
18. BRAF-mutant Non-Small Cell Lung Cancer Future Perspectives
19. BRAF-mutant Non-Small Cell Lung Cancer Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports By DelveInsight
“Type 2 Diabetes Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Type 2 Diabetes market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Type 2 Diabetes market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research